NCT01953692 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 28
- group Id
- BG001
- value
- 30
- group Id
- BG002
- value
- 31
- group Id
- BG003
- value
- 21
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 22
- group Id
- BG006
- value
- 42
- group Id
- BG007
- value
- 13
- group Id
- BG008
- value
- 6
- group Id
- BG009
- value
- 197
- units
- Participants
- groups
- description
- Participants received pembrolizumab 10 mg/kg by intravenous (IV) infusion on Day 1 of each 14-day cycle.
- id
- BG000
- title
- Cohort 1: Myelodysplastic Syndrome (MDS)
- description
- Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle OR 10 mg/kg by IV infusion on Day 1 of each 14-day cycle.
- id
- BG001
- title
- Cohort 2: Relapsed Refractory or Refractory(rR/R) Multiple Myeloma (MM)
- description
- Participants received pembrolizumab 10 mg/kg by IV infusion on Day 1 of each 14-day cycle.
- id
- BG002
- title
- Cohort 3: Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL)
- description
- Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle OR 10 mg/kg by IV infusion on Day 1 of each 14-day cycle.
- id
- BG003
- title
- Cohort 4A: R/R Primary Mediastinal B-cell Lymphoma (PMBCL)
- description
- Participants received pembrolizumab 10 mg/kg by IV infusion on Day 1 of each 14-day cycle.
- id
- BG004
- title
- Cohort 4B: Other Non-Hodgkin Lymphoma: Grey Zone, Splenic Marginal Zone, and Mantle Cell Lymphomas
- description
- Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle.
- id
- BG005
- title
- Cohort 4C: R/R Follicular Lymphoma (FL)
- description
- Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle.
- id
- BG006
- title
- Cohort 4D: R/R Diffuse Large B-Cell Lymphoma (DLBCL)
- description
- Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle + lenalidomide 20 mg orally (PO) every day (QD) for 21 consecutive days with 7 days off within 28-day cycles. The 20 mg dose of lenalidomide is the RP2D.
- id
- BG007
- title
- Cohort 5: R/R DLBCL Pembrolizumab+Lenalidomide 20 mg (RP2D)
- description
- Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle + lenalidomide 25 mg PO QD for 21 consecutive days with 7 days off within 28-day cycles. The 25 mg dose of lenalidomide was the starting dose for dose determination.
- id
- BG008
- title
- Cohort 5: R/R DLBCL Pembrolizumab+Lenalidomide 25 mg
- description
- Total of all reporting groups
- id
- BG009
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 10.4
- value
- 71.4
- group Id
- BG001
- spread
- 7.3
- value
- 67.9
- group Id
- BG002
- spread
- 12.1
- value
- 34.4
- group Id
- BG003
- spread
- 12.0
- value
- 35.2
- group Id
- BG004
- spread
- 10.9
- value
- 49.3
- group Id
- BG005
- spread
- 9.2
- value
- 62.1
- group Id
- BG006
- spread
- 11.5
- value
- 63.8
- group Id
- BG007
- spread
- 13.3
- value
- 62.6
- group Id
- BG008
- spread
- 8.4
- value
- 65.2
- group Id
- BG009
- spread
- 17.6
- value
- 57.3
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 13
- group Id
- BG002
- value
- 13
- group Id
- BG003
- value
- 14
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 9
- group Id
- BG006
- value
- 16
- group Id
- BG007
- value
- 5
- group Id
- BG008
- value
- 3
- group Id
- BG009
- value
- 83
- title
- Female
- measurements
- group Id
- BG000
- value
- 18
- group Id
- BG001
- value
- 17
- group Id
- BG002
- value
- 18
- group Id
- BG003
- value
- 7
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 13
- group Id
- BG006
- value
- 26
- group Id
- BG007
- value
- 8
- group Id
- BG008
- value
- 3
- group Id
- BG009
- value
- 114
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 2
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 8
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 26
- group Id
- BG001
- value
- 18
- group Id
- BG002
- value
- 25
- group Id
- BG003
- value
- 15
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 21
- group Id
- BG006
- value
- 40
- group Id
- BG007
- value
- 10
- group Id
- BG008
- value
- 6
- group Id
- BG009
- value
- 164
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 5
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 1
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 25
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 1
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 2
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 7
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 1
- group Id
- BG008
- value
- 1
- group Id
- BG009
- value
- 10
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 27
- group Id
- BG001
- value
- 25
- group Id
- BG002
- value
- 29
- group Id
- BG003
- value
- 20
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 19
- group Id
- BG006
- value
- 35
- group Id
- BG007
- value
- 12
- group Id
- BG008
- value
- 5
- group Id
- BG009
- value
- 176
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 2
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 1
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- population Description
- All participants who received at least one dose of study treatment.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 28
- group Id
- BG001
- value
- 30
- group Id
- BG002
- value
- 31
- group Id
- BG003
- value
- 21
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 22
- group Id
- BG006
- value
- 42
- group Id
- BG007
- value
- 13
- group Id
- BG008
- value
- 6
- group Id
- BG009
- value
- 197
- units
- Participants
- groups
- description
- Participants received pembrolizumab 10 mg/kg by intravenous (IV) infusion on Day 1 of each 14-day cycle.
- id
- BG000
- title
- Cohort 1: Myelodysplastic Syndrome (MDS)
- description
- Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle OR 10 mg/kg by IV infusion on Day 1 of each 14-day cycle.
- id
- BG001
- title
- Cohort 2: Relapsed Refractory or Refractory(rR/R) Multiple Myeloma (MM)
- description
- Participants received pembrolizumab 10 mg/kg by IV infusion on Day 1 of each 14-day cycle.
- id
- BG002
- title
- Cohort 3: Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL)
- description
- Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle OR 10 mg/kg by IV infusion on Day 1 of each 14-day cycle.
- id
- BG003
- title
- Cohort 4A: R/R Primary Mediastinal B-cell Lymphoma (PMBCL)
- description
- Participants received pembrolizumab 10 mg/kg by IV infusion on Day 1 of each 14-day cycle.
- id
- BG004
- title
- Cohort 4B: Other Non-Hodgkin Lymphoma: Grey Zone, Splenic Marginal Zone, and Mantle Cell Lymphomas
- description
- Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle.
- id
- BG005
- title
- Cohort 4C: R/R Follicular Lymphoma (FL)
- description
- Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle.
- id
- BG006
- title
- Cohort 4D: R/R Diffuse Large B-Cell Lymphoma (DLBCL)
- description
- Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle + lenalidomide 20 mg orally (PO) every day (QD) for 21 consecutive days with 7 days off within 28-day cycles. The 20 mg dose of lenalidomide is the RP2D.
- id
- BG007
- title
- Cohort 5: R/R DLBCL Pembrolizumab+Lenalidomide 20 mg (RP2D)
- description
- Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle + lenalidomide 25 mg PO QD for 21 consecutive days with 7 days off within 28-day cycles. The 25 mg dose of lenalidomide was the starting dose for dose determination.
- id
- BG008
- title
- Cohort 5: R/R DLBCL Pembrolizumab+Lenalidomide 25 mg
- description
- Total of all reporting groups
- id
- BG009
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 10.4
- value
- 71.4
- group Id
- BG001
- spread
- 7.3
- value
- 67.9
- group Id
- BG002
- spread
- 12.1
- value
- 34.4
- group Id
- BG003
- spread
- 12.0
- value
- 35.2
- group Id
- BG004
- spread
- 10.9
- value
- 49.3
- group Id
- BG005
- spread
- 9.2
- value
- 62.1
- group Id
- BG006
- spread
- 11.5
- value
- 63.8
- group Id
- BG007
- spread
- 13.3
- value
- 62.6
- group Id
- BG008
- spread
- 8.4
- value
- 65.2
- group Id
- BG009
- spread
- 17.6
- value
- 57.3
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 13
- group Id
- BG002
- value
- 13
- group Id
- BG003
- value
- 14
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 9
- group Id
- BG006
- value
- 16
- group Id
- BG007
- value
- 5
- group Id
- BG008
- value
- 3
- group Id
- BG009
- value
- 83
- title
- Female
- measurements
- group Id
- BG000
- value
- 18
- group Id
- BG001
- value
- 17
- group Id
- BG002
- value
- 18
- group Id
- BG003
- value
- 7
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 13
- group Id
- BG006
- value
- 26
- group Id
- BG007
- value
- 8
- group Id
- BG008
- value
- 3
- group Id
- BG009
- value
- 114
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 2
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 8
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 26
- group Id
- BG001
- value
- 18
- group Id
- BG002
- value
- 25
- group Id
- BG003
- value
- 15
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 21
- group Id
- BG006
- value
- 40
- group Id
- BG007
- value
- 10
- group Id
- BG008
- value
- 6
- group Id
- BG009
- value
- 164
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 5
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 1
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 25
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 1
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 2
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 7
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 1
- group Id
- BG008
- value
- 1
- group Id
- BG009
- value
- 10
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 27
- group Id
- BG001
- value
- 25
- group Id
- BG002
- value
- 29
- group Id
- BG003
- value
- 20
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 19
- group Id
- BG006
- value
- 35
- group Id
- BG007
- value
- 12
- group Id
- BG008
- value
- 5
- group Id
- BG009
- value
- 176
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 2
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 1
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- population Description
- All participants who received at least one dose of study treatment.
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle